Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENGN NASDAQ:KLRS NASDAQ:ONCY NASDAQ:TVRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENGNenGene$1.71-2.0%$5.34$1.40▼$12.25$114.22M-0.31.09 million shs714,153 shsKLRSKalaris Therapeutics$4.75+2.1%$5.63$2.14▼$11.88$112.88M0.1576,551 shs34,854 shsONCYOncolytics Biotech$0.88-5.1%$0.94$0.33▼$1.51$105.03M1.071.34 million shs1.28 million shsTVRDTvardi Therapeutics$2.95-7.1%$3.39$2.75▼$43.65$27.62M0.3357,759 shs42,253 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENGNenGene-2.25%-1.14%-76.00%-82.14%-56.28%KLRSKalaris Therapeutics-5.10%-10.75%-14.84%-48.79%+55.00%ONCYOncolytics Biotech-12.49%+14.48%+6.61%-12.49%+169.65%TVRDTvardi Therapeutics-1.55%-7.85%+0.96%-21.14%-89.34%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENGNenGene$1.71-2.0%$5.34$1.40▼$12.25$114.22M-0.31.09 million shs714,153 shsKLRSKalaris Therapeutics$4.75+2.1%$5.63$2.14▼$11.88$112.88M0.1576,551 shs34,854 shsONCYOncolytics Biotech$0.88-5.1%$0.94$0.33▼$1.51$105.03M1.071.34 million shs1.28 million shsTVRDTvardi Therapeutics$2.95-7.1%$3.39$2.75▼$43.65$27.62M0.3357,759 shs42,253 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENGNenGene-2.25%-1.14%-76.00%-82.14%-56.28%KLRSKalaris Therapeutics-5.10%-10.75%-14.84%-48.79%+55.00%ONCYOncolytics Biotech-12.49%+14.48%+6.61%-12.49%+169.65%TVRDTvardi Therapeutics-1.55%-7.85%+0.96%-21.14%-89.34%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENGNenGene 2.21Hold$12.68643.80% UpsideKLRSKalaris Therapeutics 2.75Moderate Buy$15.60228.49% UpsideONCYOncolytics Biotech 2.75Moderate Buy$8.50865.91% UpsideTVRDTvardi Therapeutics 2.43Hold$53.601,720.03% UpsideCurrent Analyst Ratings BreakdownLatest TVRD, KLRS, ONCY, and ENGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026ONCYOncolytics Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/15/2026ENGNenGene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026ENGNenGene UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$9.00 ➝ $2.005/14/2026KLRSKalaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.005/14/2026KLRSKalaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.005/13/2026KLRSKalaris Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/13/2026KLRSKalaris Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$26.00 ➝ $25.005/8/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/8/2026ENGNenGene Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$4.005/8/2026ENGNenGene Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$7.00 ➝ $4.00(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENGNenGeneN/AN/AN/AN/A$2.60 per shareN/AKLRSKalaris TherapeuticsN/AN/AN/AN/A$4.21 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A($0.04) per shareN/ATVRDTvardi Therapeutics$7.14M3.87N/AN/A$2.23 per share1.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENGNenGene-$117.30M-$2.25N/AN/AN/AN/A-55.83%-45.74%6/11/2026 (Estimated)KLRSKalaris Therapeutics-$43.44M-$2.15N/AN/AN/AN/A-72.78%-43.49%N/AONCYOncolytics Biotech-$28.76M-$0.31N/AN/AN/AN/A-2,185.97%-321.54%7/31/2026 (Estimated)TVRDTvardi Therapeutics-$18.21M-$3.10N/AN/AN/AN/A-64.17%-43.90%N/ALatest TVRD, KLRS, ONCY, and ENGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/11/2026Q2 2026ENGNenGene-$0.49N/AN/AN/AN/AN/A5/14/2026Q1 2026ONCYOncolytics Biotech-$0.05-$0.08-$0.03-$0.08N/AN/A5/12/2026Q1 2026KLRSKalaris Therapeutics-$0.52-$0.46+$0.06-$0.46N/AN/A5/8/2026Q1 2026TVRDTvardi Therapeutics-$0.65-$0.73-$0.08-$0.73N/AN/A3/31/2026Q4 2025ONCYOncolytics Biotech-$0.06-$0.08-$0.02-$0.08N/AN/A3/31/2026Q4 2025TVRDTvardi Therapeutics-$0.55-$0.78-$0.23-$0.78N/AN/A3/17/2026Q4 2025KLRSKalaris Therapeutics-$0.56-$0.44+$0.12-$0.44N/AN/A3/9/2026Q1 2026ENGNenGene-$0.55-$0.44+$0.11-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthENGNenGeneN/AN/AN/AN/AN/AKLRSKalaris TherapeuticsN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ATVRDTvardi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENGNenGene0.0911.7511.75KLRSKalaris TherapeuticsN/A12.1912.19ONCYOncolytics BiotechN/A1.381.38TVRDTvardi TherapeuticsN/A2.252.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENGNenGene64.16%KLRSKalaris Therapeutics66.05%ONCYOncolytics Biotech6.82%TVRDTvardi Therapeutics44.66%Insider OwnershipCompanyInsider OwnershipENGNenGene10.50%KLRSKalaris Therapeutics68.10%ONCYOncolytics Biotech0.10%TVRDTvardi Therapeutics7.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENGNenGene3166.99 million59.95 millionN/AKLRSKalaris Therapeutics11023.79 million7.59 millionN/AONCYOncolytics Biotech30119.35 million119.24 millionNot OptionableTVRDTvardi Therapeutics809.38 million8.69 millionN/ATVRD, KLRS, ONCY, and ENGN HeadlinesRecent News About These CompaniesTvardi Therapeutics to Participate in Upcoming Investor EventsMay 21, 2026 | globenewswire.comOppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)May 13, 2026 | theglobeandmail.comTvardi Therapeutics (TVRD) Receives a Buy from BTIGMay 11, 2026 | theglobeandmail.comTvardi: Q1 Earnings SnapshotMay 8, 2026 | wtop.comWTvardi Therapeutics Announces First Quarter 2026 Results and Provides Business UpdateMay 8, 2026 | globenewswire.comBarclays downgrades Tvardi Therapeutics (TVRD)April 21, 2026 | msn.comTvardi Therapeutics (TVRD) Price Target Decreased by 43.91% to 8.50April 9, 2026 | msn.comBarclays Reaffirms Their Hold Rating on Tvardi Therapeutics (TVRD)April 8, 2026 | theglobeandmail.comTvardi Therapeutics to Participate in the Raymond James Biotech Innovation SymposiumApril 2, 2026 | globenewswire.comTvardi: Q4 Earnings SnapshotApril 1, 2026 | stamfordadvocate.comSTvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business UpdateMarch 31, 2026 | globenewswire.comTvardi Therapeutics to Participate in Upcoming Investor ConferencesFebruary 12, 2026 | markets.businessinsider.comWe're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn RateFebruary 7, 2026 | finance.yahoo.comTvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2026 | globenewswire.comTvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical InsightsJanuary 8, 2026 | markets.businessinsider.comINVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi TherapeuticsDecember 27, 2025 | newsfilecorp.comNTVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi TherapeuticsDecember 24, 2025 | globenewswire.comINVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi TherapeuticsDecember 23, 2025 | prnewswire.comTVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi TherapeuticsDecember 21, 2025 | businesswire.comSHAREHOLDER INVESTOR REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi TherapeuticsDecember 20, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTVRD, KLRS, ONCY, and ENGN Company DescriptionsenGene NASDAQ:ENGN$1.70 -0.04 (-2.01%) As of 03:33 PM Eastern This is a fair market value price provided by Massive. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Kalaris Therapeutics NASDAQ:KLRS$4.75 +0.10 (+2.13%) As of 03:33 PM Eastern This is a fair market value price provided by Massive. Learn more.Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.Oncolytics Biotech NASDAQ:ONCY$0.88 -0.05 (-5.13%) As of 03:33 PM Eastern This is a fair market value price provided by Massive. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Tvardi Therapeutics NASDAQ:TVRD$2.94 -0.23 (-7.10%) As of 03:33 PM Eastern This is a fair market value price provided by Massive. Learn more.Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palo Alto Networks Accelerates Growth 31% on AI Demand Motorola's $1.5B Bet to Own the Skies Microsoft Build 2026 Is Really Just One Big AI Stress Test Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter What IBM's $10-Billion Quantum Project Means For Smaller Players Marvell Stock Soars on NVIDIA's Trillion-Dollar Nod HIVE Earnings Highlight AI Ambitions Beyond Bitcoin Mining Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
